Daiichi Sankyo sets up new unit in Shanghai
With an investment of approximately 1.1 billion yuan ($154 million), Daiichi Sankyo China broke ground on a new facility to produce antibody-drug conjugates (ADC) — an emerging class of highly potent pharmaceutical therapies usually used for treating cancer — in Zhangjiang Science City located in Shanghai’s Pudong New Area on Monday. As one of China’s…









